Cargando…

The extravascular implantable cardioverter‐defibrillator: The pivotal study plan

BACKGROUND: Transvenous implantable cardioverter defibrillators (TV ICD) provide life‐saving therapy for millions of patients worldwide. However, they are susceptible to several potential short‐ and long‐ term complications including cardiac perforation and pneumothorax, lead dislodgement, venous ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crozier, Ian, O'Donnell, David, Boersma, Lucas, Murgatroyd, Francis, Manlucu, Jaimie, Knight, Bradley P., Birgersdotter‐Green, Ulrika Maria, Leclercq, Christophe, Thompson, Amy, Sawchuk, Robert, Willey, Sarah, Wiggenhorn, Christopher, Friedman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Trial Study Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290824/ https://www.ncbi.nlm.nih.gov/pubmed/34322918 http://dx.doi.org/10.1111/jce.15190

Ejemplares similares

The development of the extravascular defibrillator with substernal lead placement: A new Frontier for device‐based treatment of sudden cardiac arrest
por: Thompson, Amy E., et al.
Publicado: (2022)

Three-year chronic follow-up from the pilot study of a substernal extravascular implantable cardioverter-defibrillator
por: Crozier, Ian, et al.
Publicado: (2023)

Clinical predictors of very low defibrillation threshold in the extravascular ICD
por: Murgatroyd, F, et al.
Publicado: (2023)

The extravascular implantable cardioverter-defibrillator: characterization of anatomical parameters impacting substernal implantation and defibrillation efficacy
por: Molnár, Levente, et al.
Publicado: (2021)

Evolution of extravascular implantable cardioverter-defibrillator therapy for ventricular arrhythmias
por: Römers, Hans, et al.
Publicado: (2022)

The subcutaneous implantable cardioverter-defibrillator should be reserved for niche indications
por: Yang, Yang, et al.
Publicado: (2022)

Pause-prevention pacing in an extravascular implantable cardioverter-defibrillator
por: Sagi, Venkata, et al.
Publicado: (2023)

Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator
por: Lloyd, Michael S., et al.
Publicado: (2023)

Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular‐only pacing
por: Filippatos, Gerasimos, et al.
Publicado: (2017)

Silent atrial fibrillation in patients with an implantable cardioverter defibrillator and coronary artery disease (INDICO AF) trial: study rationale and design
por: Baalman, S. W. E., et al.
Publicado: (2018)

Design and Rationale of the PRAGUE‐12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation
por: Straka, Zbyněk, et al.
Publicado: (2012)

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
por: Berry, Colin, et al.
Publicado: (2013)

Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study()
por: Moody, William E., et al.
Publicado: (2014)

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration
por: Pitcher, Alex, et al.
Publicado: (2015)

Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST‐Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design
por: Bulluck, Heerajnarain, et al.
Publicado: (2015)

Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease
por: Ripley, David P., et al.
Publicado: (2015)

Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC‐ONC Study—A Single‐Center, Blinded, Randomized Controlled Trial
por: Chung, Robin, et al.
Publicado: (2016)

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
por: Robinson, Jennifer G., et al.
Publicado: (2014)

Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy
por: Haghikia, Arash, et al.
Publicado: (2015)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
por: Budoff, Matthew, et al.
Publicado: (2018)

Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2
por: Gilgen, Nicole, et al.
Publicado: (2018)

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial
por: Hayer, Manvir K., et al.
Publicado: (2017)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
por: Jiménez, David, et al.
Publicado: (2019)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

Rationale and design of the DIGIT‐HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double‐blind, placebo‐controlled study
por: Bavendiek, Udo, et al.
Publicado: (2019)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study
por: Bunch, T. Jared, et al.
Publicado: (2019)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
por: Kirchhof, Paulus, et al.
Publicado: (2017)

Wake Forest University long‐term follow‐up of type 2 myocardial infarction: The Wake‐Up T2MI Registry
por: Jogu, Hanumantha R., et al.
Publicado: (2019)

Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol
por: Chow, Clara K., et al.
Publicado: (2021)

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)
por: Sheng, Calvin C, et al.
Publicado: (2020)

The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)
por: Wiggers, Henrik, et al.
Publicado: (2021)

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial
por: Li, Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7rdnaqh20q2n8rm4b7c1g57jvi